CXI Healthcare Technology Group Limited (KOSDAQ:900120)
South Korea · Delayed Price · Currency is KRW 2,920.00
-15.00 (-0.51%)
At close: Nov 13, 2026
KOSDAQ:900120 Income Statement
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 49,475 | 57,636 | 69,420 | 71,617 | 101,376 |
Other Revenue | - | - | - | - | 0 |
| 49,475 | 57,636 | 69,420 | 71,617 | 101,376 | |
Revenue Growth | -14.16% | -16.97% | -3.07% | -29.35% | -3.08% |
Cost of Revenue | 37,711 | 40,320 | 39,544 | 43,405 | 73,018 |
Gross Profit | 11,764 | 17,316 | 29,876 | 28,213 | 28,358 |
Selling, General & Admin | 8,821 | 7,739 | 5,326 | 10,682 | 12,638 |
Research & Development | - | -2.91 | 4,939 | 9,750 | 9,317 |
Other Operating Expenses | 17.64 | 21.23 | 136.77 | 144.34 | 152.96 |
Operating Expenses | 8,777 | 7,616 | 11,223 | 21,077 | 22,067 |
Operating Income | 2,986 | 9,700 | 18,653 | 7,136 | 6,292 |
Interest Expense | -7.02 | -4.14 | -5.06 | -2.86 | -53.79 |
Interest & Investment Income | 77.9 | 191.67 | 257.51 | 230.33 | 141.06 |
Earnings From Equity Investments | -146.77 | 323.3 | - | 235.78 | - |
Currency Exchange Gain (Loss) | -603.04 | 36.09 | -128.15 | 62.53 | -142.41 |
Other Non Operating Income (Expenses) | 19 | -12.36 | 5.39 | 27.72 | 235.82 |
EBT Excluding Unusual Items | 2,326 | 10,235 | 18,783 | 7,689 | 6,472 |
Gain (Loss) on Sale of Investments | 6,011 | 3,524 | 6,860 | - | - |
Gain (Loss) on Sale of Assets | - | - | 3,697 | - | -491.11 |
Asset Writedown | - | - | - | -161.3 | - |
Other Unusual Items | - | 7.95 | 2.42 | - | - |
Pretax Income | 8,337 | 13,766 | 29,342 | 7,528 | 5,981 |
Income Tax Expense | 269.83 | 1,026 | - | - | - |
Earnings From Continuing Operations | 8,067 | 12,741 | 29,342 | 7,528 | 5,981 |
Minority Interest in Earnings | - | - | 6.93 | 0.02 | 0.25 |
Net Income | 8,067 | 12,741 | 29,349 | 7,528 | 5,981 |
Net Income to Common | 8,067 | 12,741 | 29,349 | 7,528 | 5,981 |
Net Income Growth | -36.68% | -56.59% | 289.87% | 25.86% | 17.33% |
Shares Outstanding (Basic) | 0 | 0 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 0 | 0 | 0 | 0 | 0 |
Shares Change | 11.83% | 134.63% | -79.37% | - | 10.22% |
EPS (Basic) | 30380.05 | 53655.01 | 290000.36 | 15584.68 | 12383.07 |
EPS (Diluted) | 30380.05 | 53655.01 | 290000.36 | 15347.34 | 12000.00 |
EPS Growth | -43.38% | -81.50% | 1789.58% | 27.89% | 4.75% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -193,106 | 40,180 | 43,666 | 31,597 | 35,979 |
Free Cash Flow Per Share | -727191.61 | 169209.43 | 431465.99 | 64418.61 | 73350.61 |
Gross Margin | 23.78% | 30.04% | 43.04% | 39.39% | 27.97% |
Operating Margin | 6.04% | 16.83% | 26.87% | 9.96% | 6.21% |
Profit Margin | 16.31% | 22.11% | 42.28% | 10.51% | 5.90% |
Free Cash Flow Margin | -390.31% | 69.71% | 62.90% | 44.12% | 35.49% |
EBITDA | 33,377 | 33,142 | 43,296 | 31,116 | 32,004 |
EBITDA Margin | 67.46% | 57.50% | 62.37% | 43.45% | 31.57% |
D&A For EBITDA | 30,390 | 23,442 | 24,642 | 23,980 | 25,713 |
EBIT | 2,986 | 9,700 | 18,653 | 7,136 | 6,292 |
EBIT Margin | 6.04% | 16.83% | 26.87% | 9.96% | 6.21% |
Effective Tax Rate | 3.24% | 7.45% | - | - | - |
Advertising Expenses | 1,051 | 839.82 | 675.56 | 1,284 | 1,195 |